MPR

Hernexeos Approval Expanded to Include Treatment-Naïve HER2-Mutant NSCLC

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...
PharmExec

FDA Approves Hernexeos Under National Priority Voucher Program

The approval comes under the National Priority Voucher Program, joining Augmentin XR as one of the few approvals from the voucher program as of February 27, 2026. Hernexeos was granted a national ...
EurekAlert!

Scientists uncover novel immune mechanism in wheat tandem kinase

Wheat is grown over more land area than any other food crop. Among pathogen-driven threats to wheat, fungi top the list, causing billions of dollars of losses each year and posing a serious challenge ...
Phys.org

Kinase enzymes exist throughout tree of life—those found in bacteria may be vulnerable targets for new antibiotics

Enzymes known as kinases play a critical role in cell growth, metabolism and signaling in a multitude of organisms across the tree of life—from algae to helminths to mammals. Now, scientists have ...